RET-IN-23

RET-IN-23 is a potent and orally bioavailable small molecule inhibitor targeting RET, demonstrating significant anti-tumor efficacy in non-small cell lung cancer (NSCLC) models. It is a valuable research tool for investigating RET-driven oncogenesis in both in vitro cellular assays and in vivo xenograft studies.